Clinical Trials Logo

Primary Hyperparathyroidism clinical trials

View clinical trials related to Primary Hyperparathyroidism.

Filter by:

NCT ID: NCT00674154 Completed - Clinical trials for Vitamin D Deficiency

Effect of Vitamin D Treatment in Primary Hyperparathyroidism

Start date: May 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The primary aim of the study is to assess whether 6-months of vitamin D supplements can decrease PTH compared with placebo treatment in primary hyperparathyroidism.

NCT ID: NCT00522028 Completed - Clinical trials for Primary Hyperparathyroidism

Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial

SIPH
Start date: October 1998
Phase: N/A
Study type: Observational

The present study is a randomized, controlled trial that investigates the effects of parathyroidectomy or medical observation in mild asymptomatic pHPT on morbidity and quality of life (QoL).

NCT ID: NCT00432939 Completed - Clinical trials for Primary Hyperparathyroidism

Primary Hyperparathyroidism: Non-classical Manifestations

Start date: October 2005
Phase: N/A
Study type: Observational

This is a research study to investigate cardiovascular health in people with mild hyperparathyroidism. Previous research has suggested that severe hyperparathyroidism may be associated with abnormalities in the heart and blood vessels. It is unclear whether mild hyperparathyroidism affects cardiovascular health. This study involves the investigation of the heart and blood vessels of people with mild hyperparathyroidism. Various non-invasive laboratory and radiological test to assess cardiovascular and bone health will be done at set intervals over the course of 2 years. It is our hypothesis that patients with primary hyperparathyroidism will have subtle abnormalities in their cardiovascular system. Using state-of-the art techniques that are sufficiently sensitive to detect these subtle abnormalities, we will define cardiovascular features of this disease that have, up to now, eluded clear definition. We expect taht the extent of these findings will be related to the severity of the underlying primary hyperparathyroidism. We further hypothesize that cardiovascular manifestations may regress with successful cure of the hyperparathyroid state.